Home > Service > Drug development > Early in vitro toxicity evaluation

3D PHH Hepatotoxicity Evaluation

    The model with high clinical consistency will help you better evaluate the toxicity risk at the early stage of the drug development process, so as to optimize the follow-up test plan.

Features and advantages:

●    According to the results of testing 122 clinically marketed drugs, the 3D PHH model has a positive predictive rate of liver toxicity of over 80%. This is at least 30% higher than that of animal models.

●   The prediction sensitivity of the 3D PHH model is as high as 71.1%, more than 2 times higher than that of the 2D PHH model.

●   Suitable for both acute (2~3 d) and chronic (7~14 d) drug hepatotoxicity.


►  Drug hepatotoxicity test

►  Liver microsomal metabolism test

►  CYP450 inhibition test

►  CYP450 induction test

Primary hRPTEC nephrotoxicity

The human primary proximal renal tubule model is created using human renal proximal tubule epithelial cells (hRPTEC) human primary cells and incorporates fluid stimulation that mimics renal tubular fluid. This model closely resembles the physiological characteristics and functions of human renal tubules, allowing for more accurate assessment of early nephrotoxicity and renal cell damage through the use of cell ATP activity assays, LDH release assays, and other methods.